May 12, 2022 4:05 pm EDT iBio Reports Fiscal Third Quarter 2022 Financial Results and Provides Corporate Update
May 9, 2022 8:00 am EDT iBio Demonstrates Efficacy of an IL-2 Sparing Anti-CD25 Antibody Produced Using its FastPharming System for Treg Depletion in Cancer
May 5, 2022 4:30 pm EDT iBio to Report Fiscal 2022 Third Quarter Financial Results and Provide Corporate Update on Thursday, May 12, 2022
May 2, 2022 8:00 am EDT iBio Announces Presentation Highlighting Superior Glycosylation for Antibodies Produced in Plants
Feb 14, 2022 4:05 pm EST iBio Reports Fiscal Second Quarter 2022 Financial Results and Provides Corporate Update
Feb 7, 2022 4:30 pm EST iBio to Report Fiscal 2022 Second Quarter Financial Results and Provide Corporate Update on Monday, February 14, 2022
Jan 26, 2022 9:00 am EST iBio Announces Progression of Vaccine Program for Multi-Variant COVID-19 Disease